Seagen, Astellas Data Support Broader Indication For Padcev/Keytruda Combo

Data May Facilitate Closing Of Pfizer Merger

 
• By Joseph Haas
  
Antibody-drug conjugate
Seagen/Astellas's Padcev might now be appropriate treatment in more bladder cancer patients • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D